Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

0.6200
+0.03105.26%
Post-market: 0.6040-0.0160-2.58%19:59 EST
Volume:1.19M
Turnover:718.03K
Market Cap:74.58M
PE:-0.74
High:0.6200
Open:0.5926
Low:0.5801
Close:0.5890
52wk High:1.39
52wk Low:0.5062
Shares:120.28M
Float Shares:95.79M
Volume Ratio:1.15
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8362
EPS(LYR):-1.0033
ROE:-398.50%
ROA:-125.08%
PB:7.10
PE(LYR):-0.62

Loading ...

Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis

Reuters
·
Feb 04

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
Feb 04

Insider Traders Lose US$42k As Immunic Drops

Simply Wall St.
·
Jan 30

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 07

Immunic Inc. Faces Nasdaq Delisting Risk Over Continued Low Share Price

Reuters
·
Jan 07

Immunic Inc. Sets New CEO Pay Package for Duane Nash

Reuters
·
Jan 06

Immunic Inc. CEO to Join Evercore ISI Healthcare Conference Fireside Chat

Reuters
·
Nov 26, 2025

Immunic price target lowered to $8 from $10 at H.C. Wainwright

TIPRANKS
·
Nov 14, 2025

Immunic, Inc. : H.c. Wainwright Cuts Target Price to $8 From $10

THOMSON REUTERS
·
Nov 14, 2025

Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path

TIPRANKS
·
Nov 14, 2025

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 13, 2025

Biotech Immunic's Q3 net loss widens

Reuters
·
Nov 13, 2025

Immunic reports Q3 EPS (13c), consensus (18c)

TIPRANKS
·
Nov 13, 2025

Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate

Benzinga
·
Nov 13, 2025

Immunic Inc. reports third quarter net loss of $25.6 million

Reuters
·
Nov 13, 2025

Immunic Inc. Reports Third Quarter 2025 Financial Results and Updates on Multiple Sclerosis Trials

Reuters
·
Nov 13, 2025

Immunic Q3 Income From Operations USD -25.993 Million

THOMSON REUTERS
·
Nov 13, 2025

Immunic Q3 Basic EPS USD -0.13

THOMSON REUTERS
·
Nov 13, 2025

Immunic- Top-Line Data From Twin Phase 3 Ensure-1 and Ensure-2 Trials in Rms Expected by 2026 End

THOMSON REUTERS
·
Nov 13, 2025

Immunic: Co Does Not Have Adequate Liquidity to Fund Its Operations for at Least 12 Months From Sept 30, 2025, Without Raising Additional Capital

THOMSON REUTERS
·
Nov 13, 2025